Mélanie Karlsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mélanie Karlsen has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
David Fabre
Translational Medicine Unit, Quantitative Pharmacology Sanofi Montpellier France
2 shared publicationsDavid Marchionni
Translational Medicine Unit, Quantitative Pharmacology Sanofi Montpellier France
2 shared publications- Elisa A. M. Calvier
Translational Medicine Unit, Quantitative Pharmacology Sanofi Montpellier France
2 shared publications - Jérôme Azé
LIRMM, Laboratory of Computer Science, Robotics and Microelectronics in Montpellier, CNRS Montpellier University Montpellier France
2 shared publications - Pascal Poncelet
LIRMM, University of Montpellier, CNRS, Montpellier, France
2 shared publications - Sandra Bringay
LIRMM, CNRS, University of Montpellier
2 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (7) , e70278
PMX ‐ CovEval : A Framework Including a Simulated Pharmacokinetic Database for Covariate Model Building Methods Benchmarking
The development of new methods for covariate model building (CMB) in population pharmacokinetics (popPK) highlights the need for a standardized evaluation framework for method benchmarking. This data paper introduces PMX‐CovEval, a framework including a collection of datasets based on 127 distinct scenarios. These scenarios aim to reflect the diversity of models, available clinical studies, and covariates encountered in real‐world applications, while remaining limited enough in number to encourage their practical use. To support the evaluation of standard CMB techniques available on PsN and Monolix, model files for NONMEM and Monolix are provided alongside the datasets. Additionally, empirical Bayes estimates (EBEs) from the true base models are included to facilitate the testing of EBE‐based regression approaches. By offering pharmacokinetic (PK) datasets, model files, and EBEs in a unified resource, PMX‐CovEval provides a standardized, reproducible framework for evaluation and systematic comparison of CMB strategies in popPK. Initial benchmarking results are also provided.
- 17 June 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (7) , e70278
Open AccessPMX ‐ CovEval : A Framework Including a Simulated Pharmacokinetic Database for Covariate Model Building Methods Benchmarking
The development of new methods for covariate model building (CMB) in population pharmacokinetics (popPK) highlights the need for a standardized evaluation framework for method benchmarking. This data paper introduces PMX‐CovEval, a framework including a collection of datasets based on 127 distinct scenarios. These scenarios aim to reflect the diversity of models, available clinical studies, and covariates encountered in real‐world applications, while remaining limited enough in number to encourage their practical use. To support the evaluation of standard CMB techniques available on PsN and Monolix, model files for NONMEM and Monolix are provided alongside the datasets. Additionally, empirical Bayes estimates (EBEs) from the true base models are included to facilitate the testing of EBE‐based regression approaches. By offering pharmacokinetic (PK) datasets, model files, and EBEs in a unified resource, PMX‐CovEval provides a standardized, reproducible framework for evaluation and systematic comparison of CMB strategies in popPK. Initial benchmarking results are also provided.
- Open Access
- 20 January 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (4) , 621-639
Covariate Model Selection Approaches for Population Pharmacokinetics: A Systematic Review of Existing Methods, From SCM to AI
A growing number of covariate modeling methods have been proposed in the field of popPK modeling, but limited information exists on how they all compare. The objective of this study was to perform a systematic review of all popPK covariate modeling methods, focusing on assessing the existing knowledge on their performances. For each method of each article included in this review, evaluation setting, performance metrics along with their associated values, and relative computational times were reported when available. Evaluation settings report was done for uncertainty assessment of communicated results. Results showed that EBEs‐based ML methods stood out as the best covariate selection methods. AALASSO, a hybrid genetic algorithm, FREM with a clinical significance criterion and SCM+ with stagewise filtering were the best covariate model selection techniques—AALASSO being the very best one. Results also showed a lack of consensus on how to benchmark simulated datasets of different scenarios when evaluating method performances, but also on which metrics to use for method evaluation. We propose to systematically report TPR (sensitivity), FPR (Type I error), FNR (Type II error), TNR (specificity), covariate parameter error bias (MPE) and precision (RMSE), clinical relevance, and model fitness by means of BIC, concentration prediction error bias (MPE), and precision (RMSE) of new proposed methods and compare them with SCM. We propose to systematically combine covariate selection techniques to SCM or FFEM to allow for comparison with SCM. We also highlight the need for an open‐source benchmark of simulated datasets on a representative set of scenarios.
- 20 January 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (4) , 621-639
Open AccessCovariate Model Selection Approaches for Population Pharmacokinetics: A Systematic Review of Existing Methods, From SCM to AI
A growing number of covariate modeling methods have been proposed in the field of popPK modeling, but limited information exists on how they all compare. The objective of this study was to perform a systematic review of all popPK covariate modeling methods, focusing on assessing the existing knowledge on their performances. For each method of each article included in this review, evaluation setting, performance metrics along with their associated values, and relative computational times were reported when available. Evaluation settings report was done for uncertainty assessment of communicated results. Results showed that EBEs‐based ML methods stood out as the best covariate selection methods. AALASSO, a hybrid genetic algorithm, FREM with a clinical significance criterion and SCM+ with stagewise filtering were the best covariate model selection techniques—AALASSO being the very best one. Results also showed a lack of consensus on how to benchmark simulated datasets of different scenarios when evaluating method performances, but also on which metrics to use for method evaluation. We propose to systematically report TPR (sensitivity), FPR (Type I error), FNR (Type II error), TNR (specificity), covariate parameter error bias (MPE) and precision (RMSE), clinical relevance, and model fitness by means of BIC, concentration prediction error bias (MPE), and precision (RMSE) of new proposed methods and compare them with SCM. We propose to systematically combine covariate selection techniques to SCM or FFEM to allow for comparison with SCM. We also highlight the need for an open‐source benchmark of simulated datasets on a representative set of scenarios.